司帕沙星（CI - 978；AT - 4140）与其他抗菌药物对葡萄球菌、肠球菌及呼吸道病原体的体外活性比较
Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.
作者信息
Simor A E, Fuller S A, Low D E
机构信息
Department of Microbiology, Mount Sinai Hospital, University of Toronto, Ontario, Canada.
出版信息
Antimicrob Agents Chemother. 1990 Nov;34(11):2283-6. doi: 10.1128/AAC.34.11.2283.
Abstract
The in vitro activity of sparfloxacin (CI-978; AT-4140) was compared with those of other antimicrobial agents against isolates of staphylococci, enterococci, and various respiratory tract pathogens. Sparfloxacin was the most active drug tested against staphylococci (MIC for 90% of the strains tested [MIC90], 0.125 micrograms/ml) and enterococci (MIC90, 1.0 microgram/ml). It was also active against Haemophilus influenzae (MIC90, less than or equal to 0.06 microgram/ml), Moraxella (Branhamella) catarrhalis (MIC90, 0.125 microgram/ml), Streptococcus pneumoniae (MIC90, 0.5 microgram/ml), and Streptococcus pyogenes (MIC90, 1.0 microgram/ml).
摘要
将司帕沙星（CI-978；AT-4140）的体外活性与其他抗菌药物针对葡萄球菌、肠球菌及各种呼吸道病原体分离株的活性进行了比较。司帕沙星是所测试药物中对葡萄球菌（90%测试菌株的最低抑菌浓度[MIC90]，0.125微克/毫升）和肠球菌（MIC90，1.0微克/毫升）活性最强的药物。它对流感嗜血杆菌（MIC90，小于或等于0.06微克/毫升）、卡他莫拉菌（布兰汉菌属）（MIC90，0.125微克/毫升）、肺炎链球菌（MIC90，0.5微克/毫升）和化脓性链球菌（MIC90，1.0微克/毫升）也有活性。
相似文献
1
Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.司帕沙星（CI - 978；AT - 4140）与其他抗菌药物对葡萄球菌、肠球菌及呼吸道病原体的体外活性比较
Antimicrob Agents Chemother. 1990 Nov;34(11):2283-6. doi: 10.1128/AAC.34.11.2283.
2
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.利用美国190个医疗中心分离出的14000多种病原体的检测结果，对司帕沙星的活性和抗菌谱进行体外比较评估。SPAR研究小组。
Diagn Microbiol Infect Dis. 1997 Nov;29(3):173-86. doi: 10.1016/s0732-8893(97)81807-x.
3
Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.从社区获得性下呼吸道感染成年患者中分离出的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌菌株对司帕沙星及其他抗生素的敏感性：一项欧洲多中心研究。SPAR研究组。抗生素耐药性监测计划。
J Antimicrob Chemother. 1998 Feb;41(2):207-14. doi: 10.1093/jac/41.2.207.
4
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.针对在美国和加拿大分离出的24940种病原体的司帕沙星活性和抗菌谱的体外评估，最终分析。
Diagn Microbiol Infect Dis. 1998 May;31(1):313-25. doi: 10.1016/s0732-8893(97)00247-2.
5
Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.与其他11种药物相比，吉米沙星对流感嗜血杆菌和卡他莫拉菌的活性及抗生素后效应。
Antimicrob Agents Chemother. 2000 Mar;44(3):633-9. doi: 10.1128/AAC.44.3.633-639.2000.
6
BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.BAY 12 - 8039，一种新型氟喹诺酮类药物。对重要呼吸道病原体的活性。
Diagn Microbiol Infect Dis. 1998 Sep;32(1):45-50. doi: 10.1016/s0732-8893(98)00042-x.
7
In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.新型喹诺酮抗菌剂司帕沙星（AT-4140和CI-978）对嗜血杆菌和革兰氏阳性球菌的体外活性。
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):355-60. doi: 10.1016/0732-8893(91)90028-e.
8
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
J Chemother. 2002 Feb;14(1):19-24. doi: 10.1179/joc.2002.14.1.19.
9
[National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
Rev Esp Quimioter. 2000 Mar;13(1):37-43.
10
In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.新型酮内酯类药物HMR 3647与对照口服抗生素对加拿大呼吸道分离的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的体外活性
Diagn Microbiol Infect Dis. 1999 Sep;35(1):37-44. doi: 10.1016/s0732-8893(99)00053-x.
引用本文的文献
1
Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.司帕沙星。对其在下呼吸道感染中的抗菌活性、药代动力学特性、临床疗效及耐受性的综述。
Drugs. 1997 Apr;53(4):700-25. doi: 10.2165/00003495-199753040-00010.
2
Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.司帕沙星的药代动力学及对肺炎球菌的血清杀菌活性
Antimicrob Agents Chemother. 1996 Mar;40(3):776-9. doi: 10.1128/AAC.40.3.776.
3
Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.司帕沙星的多剂量药代动力学及其对粪便菌群的影响。
Antimicrob Agents Chemother. 1994 Mar;38(3):455-9. doi: 10.1128/AAC.38.3.455.
4
New quinolones and gram-positive bacteria.新型喹诺酮类药物与革兰氏阳性菌
Antimicrob Agents Chemother. 1994 Feb;38(2):163-9. doi: 10.1128/AAC.38.2.163.
5
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.在使用耐环丙沙星临床分离株预测组进行测试后，对左氧氟沙星和司帕沙星纸片扩散药敏试验标准的建议修改。
J Clin Microbiol. 1995 Jan;33(1):146-8. doi: 10.1128/jcm.33.1.146-148.1995.
6
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.司帕沙星、妥舒沙星、环丙沙星和氟罗沙星的体外活性。
Antimicrob Agents Chemother. 1991 May;35(5):955-60. doi: 10.1128/AAC.35.5.955.
7
Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.洛美沙星。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1991 Dec;42(6):1018-60. doi: 10.2165/00003495-199142060-00009.
8
Future directions in antimicrobial chemotherapy.抗菌化疗的未来发展方向。
Pharm Weekbl Sci. 1992 Aug 21;14(4A):229-44. doi: 10.1007/BF01962545.
9
In vitro activity of sparfloxacin compared with those of five other quinolones.
Antimicrob Agents Chemother. 1992 Mar;36(3):558-65. doi: 10.1128/AAC.36.3.558.
10
In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.司帕沙星及其他三种氟喹诺酮类药物对耐甲氧西林金黄色葡萄球菌和表皮葡萄球菌的体外活性
Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):55-8. doi: 10.1007/BF01971273.
本文引用的文献
1
Treatment of skin and soft tissue infections with oral ciprofloxacin.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:153-7. doi: 10.1093/jac/18.supplement_d.153.
2
Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.口服环丙沙星治疗骨、关节和软组织感染。
Antimicrob Agents Chemother. 1987 Feb;31(2):151-5. doi: 10.1128/AAC.31.2.151.
3
Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.
Am J Med. 1987 Apr 27;82(4A):215-9.
4
Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women.100毫克与250毫克单剂量环丙沙星治疗女性单纯性尿路感染的疗效比较
Antimicrob Agents Chemother. 1987 Feb;31(2):354-6. doi: 10.1128/AAC.31.2.354.
5
Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients.新型4-喹诺酮类抗生素环丙沙星治疗发热性中性粒细胞减少症患者的初步评估。
J Antimicrob Chemother. 1986 Nov;18 Suppl D:165-74. doi: 10.1093/jac/18.supplement_d.165.
6
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.八种新型喹诺酮类药物与萘啶酸的体外活性比较
J Antimicrob Chemother. 1986 Nov;18 Suppl D:1-20. doi: 10.1093/jac/18.supplement_d.1.
7
In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains.PD 117,596与对照抗生素对448株临床细菌菌株的体外活性
Antimicrob Agents Chemother. 1988 Sep;32(9):1450-5. doi: 10.1128/AAC.32.9.1450.
8
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.氟喹诺酮类药物：结构、作用机制与耐药性以及体外活性谱
Antimicrob Agents Chemother. 1985 Oct;28(4):581-6. doi: 10.1128/AAC.28.4.581.
9
In-vitro activity of newer quinolones against aerobic bacteria.新型喹诺酮类药物对需氧菌的体外活性
J Antimicrob Chemother. 1986 Apr;17 Suppl B:29-39. doi: 10.1093/jac/17.suppl_b.29.
10
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.氟喹诺酮类药物：人体药理学、临床应用及毒性
Antimicrob Agents Chemother. 1985 Nov;28(5):716-21. doi: 10.1128/AAC.28.5.716.
Zotero 插件